Exploiting In Vivo Precision Pharmacology Techniques to Understand Opioid Receptor Signaling in Specific Circuits, Cell Types, and Subcellular Compartments (R61/R33 - Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This funding opportunity aims to support the development and the application of novel pharmacological approaches to manipulate signaling mediated by endogenous opioid receptors in defined circuits, cell-types or subcellular compartments in live organisms.  


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): October 17, 2019

RFA-DA-20-019 Expiration Date October 18, 2019

Agency Website

Amount Description

Application direct costs are limited to $300,000 during each year of the R61 phase and $400,000 during each year of the R33 phase.

Funding Type





Medical - Basic Science
Medical - Translational

External Deadline

October 17, 2019